Axogen develops and markets regenerative medicine products for peripheral nerve repair. Its portfolio includes processed nerve allografts such as Avance Nerve Graft, nerve connectors, wraps and related tools used by surgeons to reconstruct damaged or severed nerves. The company serves trauma, reconstructive and oral-maxillofacial surgical markets where standard sutures alone are often insufficient for meaningful nerve recovery.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 56.7 | — | 0.6 | — |
| Q3 2025 | 60.1 | — | 0.7 | — |
| Q4 2025 | 59.9 | — | -13.2 | — |
| Q1 2026 | 61.5 | — | -19.6 | — |
| Q2 2026 | 69.7 | 23.1% | -1.5 | -361.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AtaiBeckley Inc. (ATAI), Visteon Corporation (VC), Slide Insurance Holdings, Inc. (SLDE), Trump Media & Technology Group Corp. (DJT), Veeco Instruments Inc. (VECO), TMC the metals company Inc. (TMC)